依度沙班为新型口服抗凝药,于2015年1月8日经美国FDA批准用于降低非瓣膜性心房颤动患者的卒中和系统性栓塞风险。本文对其作用机制、药理学、药动学、临床评价、用法用量、安全性、不良反应等方面作了综述。 Edo Saban, a new oral anticoagulant, was approved by the U.S. FDA on January 8, 2015 to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. This article reviews its mechanism of action, pharmacology, pharmacokinetics, clinical evaluation, usage and dosage, safety, adverse reactions and so on.